Skip to content
Menu

OKYO Pharma Limited OKYO

Full chart Compare
Set alert

Price alert · OKYO

All alert types
1.12 USD -0.04 (-3.78%)

As ofNov 20, 2026, 3:13 PM EST

1.09 Day range 1.18
1.00 52-week range 3.20
YTD
-46.08%
1 year
-41.57%

 

No chart data for this range yet.
Market cap
57.99M
EPS (ttm)
-0.24
Shares out
33.84M
YTD return
-46.08%
1-year return
-41.57%
50-day average
1.08
200-day average
1.23
Enterprise value
34.04M
Volume
51.84K
Avg volume
142.45K
Open
1.18
Previous close
1.16
Day's range
1.09 – 1.18
52-week range
1.00 – 3.20
Beta
-3.36
Price target
7.00 (+527.2%)

Key statistics

Free cash flow
-3.09M
Total cash
4.05M
Total debt
2.22M
Short % of float
1.00%

Fundamental scorecard

4 of 25 checks passed on OKYO’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Mar 31, 2026.

Financials — quick view

All financials
OKYO Revenue — annual 0
OKYO Net income — annual -8.95M
OKYO EPS — annual -0.24

Upgrades / downgrades

OKYO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 24, 2024HC Wainwright & Co.reitBuyBuy
Oct 16, 2024HC Wainwright & Co.reitBuyBuy
Aug 27, 2024HC Wainwright & Co.reitBuyBuy
Jul 12, 2024HC Wainwright & Co.reitBuyBuy
Jul 11, 2024HC Wainwright & Co.reitBuyBuy
Mar 22, 2024HC Wainwright & Co.mainBuyBuy

About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on OKYO — it syncs with the Stock Master app.

Institution ownership

OKYO institution ownership
Holder% heldSharesValueReported
Barclays Plc2.84%961,0001.02MSep 29, 2024
Cerity Partners LLC0.04%12,81213.58KSep 29, 2024
Geode Capital Management, LLC0.04%12,09012.81KSep 29, 2024
Citadel Advisors Llc0.04%14,87615.77KSep 29, 2024
UBS Group AG0.00%525556Sep 29, 2024
Continuum Advisory, Llc0.00%5052Sep 29, 2024

Fund ownership

OKYO fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.04%12,09012.81KOct 30, 2024